Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
5.68
-0.27 (-4.54%)
At close: Aug 1, 2025, 4:00 PM
5.61
-0.07 (-1.23%)
After-hours: Aug 1, 2025, 7:59 PM EDT

Company Description

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States.

The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited.

Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals logo
CountryUnited States
Founded2013
IPO DateApr 16, 2021
IndustryBiotechnology
SectorHealthcare
Employees800
CEOChristopher Gibson

Contact Details

Address:
41 South Rio Grande Street
Salt Lake City, Utah 84101
United States
Phone385 269 0203
Websiterecursion.com

Stock Details

Ticker SymbolRXRX
ExchangeNASDAQ
Stock TypeCommon Stock
Share ClassClass A Shares
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$18.00
CIK Code0001601830
CUSIP Number75629V104
ISIN NumberUS75629V1044
Employer ID46-4099738
SIC Code2836

Key Executives

NamePosition
Dr. Christopher C. Gibson Ph.D.Co-Founder, Chief Executive Officer and Director
Ben R. TaylorChief Financial Officer and President of Recursion UK
Dr. David J. Mauro M.D., Ph.D.Chief Medical Officer
Dr. Najat Khan Ph.D.Chief Research & Development Officer, Chief Commercial Officer and Director
Kristen Rushton M.B.A.Chief Operating Officer
Kevin LeggatVice President of Finance and Accounting
Benjamin Mabey M.S.Chief Technology Officer
Dr. David Hallett Ph.D.Chief Scientific Officer
Nathan Hatfield J.D., M.B.A.Chief Legal Officer and General Counsel
Erica FoxChief People and Impact Officer

Latest SEC Filings

DateTypeTitle
Jul 8, 20258-KCurrent Report
Jul 8, 2025424B7Filing
Jun 18, 20258-KCurrent Report
Jun 10, 20258-KCurrent Report
May 9, 20258-KCurrent Report
May 9, 2025424B7Filing
May 5, 2025S-8Securities to be offered to employees in employee benefit plans
May 5, 202510-QQuarterly Report
May 5, 20258-KCurrent Report
Apr 28, 2025ARSFiling